Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 13/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.57 |
| ▸ | DBH | P09172 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 3/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6774851 | 0.81 | DBH (0.45) | CYP11B1CYP11B2DBHCRHBPCRHR2 | |
| SCHEMBL7658010 | 0.81 | CYP11B1 (0.53) | CYP11B1CYP11B2 | |
| SCHEMBL6781178 | 0.80 | CYP11B1 (0.47) | CYP11B1CYP11B2DBHCRHBPCRHR2 | |
| SCHEMBL4161202 | 0.74 | HPGD (0.49) | DBHCRHBPCRHR2SMN1; SMN2MAPT | |
| SCHEMBL31174285 | 0.74 | HPGD (0.49) | DBHCRHBPCRHR2SMN1; SMN2MAPT | |
| SCHEMBL6774918 | 0.72 | CYP11B1 (0.82) | CYP11B1CYP11B2 | |
| SCHEMBL6771366 | 0.72 | MAOB (0.48) | CYP11B1CYP11B2 | |
| SCHEMBL9837445 | 0.72 | ITGA4 (0.42) | CYP11B1CYP11B2 | |
| SCHEMBL9837440 | 0.72 | ITGA4 (0.42) | CYP11B1CYP11B2 | |
| SCHEMBL7187666 | 0.71 | CYP11B1 (0.60) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040171844-A1 | Dihydro-2H-naphthalene-1-one inhibitors of ras farnesyl transferase | LEONARD DANIELE MARIE (US) | 2004-09-02 | — | — | US | disclosed |
| US-20040063770-A1 | Method for treating Alzheimer's disease | WARNER-LAMBERT COMPANY | 2004-04-01 | — | — | US | disclosed |
| US-20030232790-A1 | Dihydro-2h-napthalene-1-one inhibitors of ras farnesyl transferase | WARNER-LAMBERT COMPANY | 2003-12-18 | — | — | US | disclosed |
| EP-1276724-A2 | DIHYDRO-2H-NAPHTHALENE-1-ONE INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20010051642-A1 | Method for treating Alzheimer's disease | AHN KYUNGHYE (US) | 2001-12-13 | — | — | US | disclosed |
| WO-2001079179-A2 | DIHYDRO-2H-NAPHTHALENE-1-ONE INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171844-A1 | Dihydro-2H-naphthalene-1-one inhibitors of ras farnesyl transferase | NRAS, HRAS, FNTB | CYP11B1 507/4885CYP11B2 1099/4885DBH 2103/4885 |
| US-20040063770-A1 | Method for treating Alzheimer's disease | BACE1, BACE2, PSEN1 | CYP11B1 83/4885CYP11B2 110/4885DBH 94/4885 |
| US-20010051642-A1 | Method for treating Alzheimer's disease | BACE1, BACE2, PSEN1 | CYP11B1 83/4885CYP11B2 110/4885DBH 94/4885 |
| US-20030232790-A1 | Dihydro-2h-napthalene-1-one inhibitors of ras farnesyl transferase | NRAS, FNTA, CYP46A1 | CYP11B1 206/4885CYP11B2 430/4885DBH 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.